Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data
CNS Drugs · 2024
DOI: 10.1007/s40263-024-01079-y ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Drugs, 2024. Verfasst von Hasan Çağın Lenk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Psychopharmacology, Diakonhjemmet Hospital, Vinderen, PO Box 85, 0319, Oslo, Norway. hcaginlenk@gmail.com. Hauptthemen laut MEDLINE: Antipsychotic Agents, Clozapine, Drug Monitoring. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Helse Sør-Øst RHF, Horizon 2020, University of Oslo.
Abstract (Originalsprache)
INTRODUCTION: Adequate antipsychotic treatment intensity is required before diagnosing resistant schizophrenia and initiating clozapine treatment. We aimed to investigate potential rapid drug metabolism underlying low dose-adjusted serum concentration (CD) of non-clozapine atypical antipsychotics preceding clozapine treatment. METHODS: Patients using non-clozapine, atypical antipsychotics (aripiprazole, risperidone, olanzapine, or quetiapine) within 1 year before starting clozapine were included in this study from a therapeutic drug monitoring service in Oslo, Norway, between 2005 and 2023. Patients were assigned into low CD (LCD) and normal CD (NCD) subgroups. Using a reference sample with 147,964 antipsychotic measurements, LCD was defined as CDs below the 25th percentile, while patients with NCD exhibited CDs between the 25th and 75th percentile of the respective reference measurements. Metabolic ratios, doses, and frequency of subtherapeutic levels of non-clozapine antipsychotics were compared between LCD and NCD groups. RESULTS: Preceding clozapine treatment, 110 out of 272 included patients (40.4%) were identified with LCD. Compared with the NCD group, LCD patients exhibited higher metabolic ratios of olanzapine (1.5-fold; p < 0.001), quetiapine (3.0-fold; p < 0.001), and risperidone (6.0-fold; p < 0.001). Metabolic ratio differences were independent of smoking and CYP2D6 genotype for olanzapine (p = 0.008) and risperidone (p = 0.016), respectively. Despite higher doses of olanzapine (1.25-fold; p = 0.054) and quetiapine (1.6-fold; p = 0.001) in LCD versus NCD patients, faster metabolism among the former was accompanied by higher frequencies of subtherapeutic levels of olanzapine (3.3-fold; p = 0.044) and quetiapine (1.8-fold; p = 0.005). CONCLUSION: LCD and associated rapid metabolism of non-clozapine antipsychotics is frequent before starting clozapine treatment. For olanzapine and quetiapine, this is associated with significantly increased risk of having subtherapeutic concentrations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Psychopharmacology, Diakonhjemmet Hospital, Vinderen, PO Box 85, 0319, Oslo, Norway. hcaginlenk@gmail.com.
- Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Oslo, Norway. hcaginlenk@gmail.com.
- Division of Mental Health and Addiction, NORMENT, Centre for Mental Disorders Research, Institute of Clinical Medicine, Oslo University Hospital, University of Oslo, Oslo, Norway. hcaginlenk@gmail.com.
- Center for Psychopharmacology, Diakonhjemmet Hospital, Vinderen, PO Box 85, 0319, Oslo, Norway.
- Division of Mental Health and Addiction, NORMENT, Centre for Mental Disorders Research, Institute of Clinical Medicine, Oslo University Hospital, University of Oslo, Oslo, Norway.
- KG Jebsen Centre for Neurodevelopmental disorders, University of Oslo, Oslo University Hospital, Oslo, Norway.
ORCID-Profile: Hasan Çağın Lenk, Robert Løvsletten Smith, Kevin S O'Connell, Ole A Andreassen, Espen Molden
Förderung
- Helse Sør-Øst RHF
- Horizon 2020
- University of Oslo
Zitieren
APA
Lenk, H. Ç., Smith, R. L., O'Connell, K. S., Andreassen, O. A., & Molden, E. (2024). Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data. CNS Drugs. https://doi.org/10.1007/s40263-024-01079-y
Vancouver
Lenk HÇ, Smith RL, O'Connell KS, Andreassen OA, Molden E. Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data. CNS Drugs. 2024. doi:10.1007/s40263-024-01079-y
BibTeX
@article{Lenk2024,
author = {Lenk, Hasan Çağın and Smith, Robert Løvsletten and O'Connell, Kevin S and Andreassen, Ole A and Molden, Espen},
title = {Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data},
journal = {CNS Drugs},
year = {2024},
doi = {10.1007/s40263-024-01079-y}
}
EUVIMED